198 related articles for article (PubMed ID: 27212431)
1. Digestive neuroendocrine neoplasms: A 2016 overview.
Merola E; Rinzivillo M; Cicchese N; Capurso G; Panzuto F; Delle Fave G
Dig Liver Dis; 2016 Aug; 48(8):829-35. PubMed ID: 27212431
[TBL] [Abstract][Full Text] [Related]
2. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
3. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
4. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.
Klöppel G; Rindi G; Anlauf M; Perren A; Komminoth P
Virchows Arch; 2007 Aug; 451 Suppl 1():S9-27. PubMed ID: 17684761
[TBL] [Abstract][Full Text] [Related]
5. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Naraev BG; Strosberg JR; Halfdanarson TR
Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
[TBL] [Abstract][Full Text] [Related]
6. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options.
Merola E; Prasad V; Pascher A; Pape UF; Arsenic R; Denecke T; Fehrenbach U; Wiedenmann B; Pavel ME
Neuroendocrinology; 2020; 110(6):517-524. PubMed ID: 31484182
[TBL] [Abstract][Full Text] [Related]
8. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Ito T; Igarashi H; Jensen RT; Takayanagi R
Fukuoka Igaku Zasshi; 2012 Jul; 103(7):131-7. PubMed ID: 22978065
[No Abstract] [Full Text] [Related]
9. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
10. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
Narayanan S; Kunz PL
Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
[TBL] [Abstract][Full Text] [Related]
11. Lung and digestive neuroendocrine neoplasms. From WHO classification to biomarker screening: Which perspectives?
Scoazec JY
Ann Endocrinol (Paris); 2019 Jun; 80(3):163-165. PubMed ID: 31064659
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms.
Vijayvergia N; Dasari A
Curr Treat Options Oncol; 2020 Oct; 21(12):96. PubMed ID: 33029680
[TBL] [Abstract][Full Text] [Related]
14. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
15. Targeted agents in treatment of neuroendocrine tumors of pancreas.
Karampelas IN; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives.
Modica R; Liccardi A; Minotta R; Cannavale G; Benevento E; Colao A
Expert Rev Endocrinol Metab; 2022 Sep; 17(5):389-403. PubMed ID: 35822906
[TBL] [Abstract][Full Text] [Related]
17. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
[TBL] [Abstract][Full Text] [Related]
18. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
Basu B; Sirohi B; Corrie P
Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine neoplasms.
Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
